Translations:Research/key-initiatives/ras/spokes-funding/19/en

From loveco.care
Revision as of 23:27, 29 October 2019 by FuzzyBot (talk | contribs) (Importing a new version from external source)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

The NCI Clinical Proteomic Tumor Analysis Consortium has awarded contracts to the Fred Hutchinson Cancer Research Center (Dr. Amanda Paulovich), the Moffitt Cancer Center (Dr. John Koomen), and the Broad Institute (Dr. Steven Carr). They will develop quantitative immuno-multiple reaction monitoring (MRM) assays to measure important peptides and phospho-peptides in the RAS pathway. Data from these assays will provide a valuable link between phenotypes and genotypes in cancers. For more details please see the blog post in RAS Central. 

||
From left to right: Dr. Amanda Paulovich, Dr. John Koomen, Dr. Steve Carr
Retrieved from "http://www.loveco.care/index.php?title=Translations:Research/key-initiatives/ras/spokes-funding/19/en&oldid=10506"